KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Payables (2016 - 2025)

Historic Payables for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $11.8 million.

  • CRISPR Therapeutics AG's Payables fell 2426.5% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 2426.5%. This contributed to the annual value of $14.7 million for FY2024, which is 6144.13% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Payables is $11.8 million, which was down 2426.5% from $9.8 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Payables peaked at $45.2 million during Q1 2023, and registered a low of $9.5 million during Q2 2024.
  • Its 5-year average for Payables is $20.4 million, with a median of $15.6 million in 2024.
  • In the last 5 years, CRISPR Therapeutics AG's Payables surged by 21586.51% in 2022 and then tumbled by 6573.87% in 2024.
  • CRISPR Therapeutics AG's Payables (Quarter) stood at $14.8 million in 2021, then skyrocketed by 85.12% to $27.4 million in 2022, then surged by 39.08% to $38.1 million in 2023, then crashed by 61.44% to $14.7 million in 2024, then decreased by 19.79% to $11.8 million in 2025.
  • Its Payables was $11.8 million in Q3 2025, compared to $9.8 million in Q2 2025 and $13.1 million in Q1 2025.